Huons Global to Produce Russian COVID-19 Vaccine with Single Dose Administration

"Sputnik Light with single-dose regimen to be produced alongside Sputnik V"

Sputnik Light (Photo by Huons Global)

[Asia Economy Reporter Kim Ji-hee] Huons Global Consortium will also be responsible for the production of the single-dose Russian COVID-19 vaccine, 'Sputnik Light.'

The Huons Global Consortium, led by Huons Global, announced on the 28th that it has recently completed final discussions with the Russian sovereign wealth fund (RDIF) regarding the domestic production of Sputnik Light. A representative of the Huons Global Consortium stated, "At the request of RDIF, we decided to produce Sputnik Light alongside Sputnik V," adding, "The production of Sputnik Light will also be carried out in cooperation with Prestige BioPharma, Humedix, and Boran Pharma, which are part of the Huons Global Consortium."

They continued, "We have already secured the cells for cell culture and the virus needed for the production of the Sputnik Light vaccine," and added, "Next month, Russian technicians will visit Korea to proceed with technology transfer for both Sputnik V and Sputnik Light."

Sputnik Light is a vaccine developed by the Gamaleya National Research Center of Epidemiology and Microbiology under the Russian Ministry of Health, which received approval for use in Russia in May. It has also been approved in Russia, Kyrgyzstan, Venezuela, and Mongolia to date.

Sputnik Light uses adenovirus as a vector, similar to Sputnik V. Unlike Sputnik V, which uses two types of vectors, Sputnik Light uses only one type of vector (adenovirus type 26), allowing vaccination to be completed with a single dose. The preventive efficacy is 79.4%, and the duration of immunity is known to be about 3 to 4 months. Phase 3 clinical trials have been underway since the end of February, involving about 7,000 participants in Russia, the United Arab Emirates (UAE), Ghana, and other countries.

The Huons Global Consortium signed a technology transfer agreement with RDIF in April for the production of the Sputnik V vaccine. Sputnik V has been approved in 67 countries, including Russia. Approval procedures with the World Health Organization (WHO) and the European Medicines Agency (EMA) are also underway.

The Huons Global Consortium plans to start pilot production from August. After validation and other processes, full-scale production is expected to begin from September to October. The goal is to produce 20 to 30 million doses per month by the end of the year, and from next year, when facility expansion is completed, both production and shipment are expected to stabilize.

This content was produced with the assistance of AI translation services.